Sakshi Bajoria
Overview
Explore the profile of Sakshi Bajoria including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
34
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumru O, Bajoria S, Kaur K, Hickey J, Van Slyke G, Doering J, et al.
Hum Vaccin Immunother
. 2023 Nov;
19(2):2264594.
PMID: 37932241
Second-generation COVID-19 vaccines with improved immunogenicity (e.g., breadth, duration) and availability (e.g., lower costs, refrigerator stable) are needed to enhance global coverage. In this work, we formulated a clinical-stage SARS-CoV-2...
2.
Bajoria S, Kumru O, Doering J, Berman K, Van Slyke G, Prigodich A, et al.
Vaccines (Basel)
. 2023 Jun;
11(6).
PMID: 37376419
Aluminum-salt vaccine adjuvants (alum) are commercially available as micron-sized particles with varying chemical composition and crystallinity. There are reports of enhanced adjuvanticity when the alum's particle size is reduced to...
3.
Bajoria S, Antunez L, Kumru O, Klempner M, Wang Y, Cavacini L, et al.
J Pharm Sci
. 2023 Apr;
112(7):1832-1844.
PMID: 37040833
Enterotoxigenic Escherichia coli (ETEC) is a common cause for diarrheal infections in children in low- and middle-income countries (LMICs). To date, no ETEC vaccine candidates have been approved. Passive immunization...
4.
Rodriguez-Aponte S, Naranjo C, Johnston R, Dalvie N, Crowell L, Bajoria S, et al.
Biotechnol Bioeng
. 2023 Mar;
121(8):2423-2434.
PMID: 36929469
Analytical characterization of proteins is a critical task for developing therapeutics and subunit vaccine candidates. Assessing candidates with a battery of biophysical assays can inform the selection of one that...
5.
Rodriguez-Aponte S, Dalvie N, Wong T, Johnston R, Naranjo C, Bajoria S, et al.
Vaccine
. 2023 Jan;
41(5):1108-1118.
PMID: 36610932
There is a continued need for sarbecovirus vaccines that can be manufactured and distributed in low- and middle-income countries (LMICs). Subunit protein vaccines are manufactured at large scales at low...
6.
Bajoria S, Kaur K, Kumru O, Van Slyke G, Doering J, Novak H, et al.
Hum Vaccin Immunother
. 2022 Jun;
18(5):2079346.
PMID: 35666264
Low-cost, refrigerator-stable COVID-19 vaccines will facilitate global access and improve vaccine coverage in low- and middle-income countries. To this end, subunit-based approaches targeting the receptor-binding domain (RBD) of SARS-CoV-2 Spike...
7.
Dalvie N, Tostanoski L, Rodriguez-Aponte S, Kaur K, Bajoria S, Kumru O, et al.
Sci Adv
. 2022 Mar;
8(11):eabl6015.
PMID: 35294244
Authorized vaccines against SARS-CoV-2 remain less available in low- and middle-income countries due to insufficient supply, high costs, and storage requirements. Global immunity could still benefit from new vaccines using...
8.
Dalvie N, Tostanoski L, Rodriguez-Aponte S, Kaur K, Bajoria S, Kumru O, et al.
bioRxiv
. 2021 Jul;
PMID: 34282417
Vaccines against SARS-CoV-2 have been distributed at massive scale in developed countries, and have been effective at preventing COVID-19. Access to vaccines is limited, however, in low- and middle-income countries...
9.
Perruzza L, Jaconi S, Lombardo G, Pinna D, Strati F, Morone D, et al.
Front Immunol
. 2020 Jun;
11:1011.
PMID: 32582158
infection is one of the most common causes of bacterial gastroenteritis worldwide and a major global health threat due to the rapid development of antibiotic resistance. Currently, there are no...